FDA approves mavacamten, first treatment for obstructive hypertrophic cardiomyopathy

The FDA approved mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy, the first cardiac myosin inhibitor to be permitted for use in the United States, Bristol Myers Squibb announced.
Mavacamten (Camzyos, Bristol Myers Squibb) is the first and only FDA-approved allosteric and reversible inhibitor selective for cardiac myosin that targets the underlying pathophysiology of obstructive HCM, available as 2.5 mg, 5 mg, 10 mg and 15 mg capsules. The FDA granted a breakthrough therapy designation to mavacamten for the treatment of adults with symptomatic New York Heart

The FDA approved mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy, the first cardiac myosin inhibitor to be permitted for use in the United States, Bristol Myers Squibb announced.
Mavacamten (Camzyos, Bristol Myers Squibb) is the first and only FDA-approved allosteric and reversible inhibitor selective for cardiac myosin that targets the underlying pathophysiology of obstructive HCM, available as 2.5 mg, 5 mg, 10 mg and 15 mg capsules. The FDA granted a breakthrough therapy designation to mavacamten for the treatment of adults with symptomatic New York Heart